Innate Pharma
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.89
- Today's High:
- $3.0538
- Open Price:
- $2.91
- 52W Low:
- $1.9
- 52W High:
- $3.97
- Prev. Close:
- $3.03
- Volume:
- 725
Company Statistics
- Market Cap.:
- $253.80 million
- Book Value:
- 0.675
- Revenue TTM:
- $57.67 million
- Operating Margin TTM:
- -28.48%
- Gross Profit TTM:
- $57.67 million
- Profit Margin:
- -100.74%
- Return on Assets TTM:
- -4.32%
- Return on Equity TTM:
- -71.75%
Company Profile
Innate Pharma had its IPO on 2019-10-17 under the ticker symbol IPHA.
The company operates in the Healthcare sector and Biotechnology industry. Innate Pharma has a staff strength of 211 employees.
Stock update
Shares of Innate Pharma opened at $2.91 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.89 - $3.05, and closed at $2.97.
This is a -1.98% slip from the previous day's closing price.
A total volume of 725 shares were traded at the close of the day’s session.
In the last one week, shares of Innate Pharma have increased by +1.78%.
Innate Pharma's Key Ratios
Innate Pharma has a market cap of $253.80 million, indicating a price to book ratio of 1.3445 and a price to sales ratio of 3.0969.
In the last 12-months Innate Pharma’s revenue was $57.67 million with a gross profit of $57.67 million and an EBITDA of $-12020000. The EBITDA ratio measures Innate Pharma's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Innate Pharma’s operating margin was -28.48% while its return on assets stood at -4.32% with a return of equity of -71.75%.
In Q2, Innate Pharma’s quarterly earnings growth was a positive 0% while revenue growth was a positive 6.1%.
Innate Pharma’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.77 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Innate Pharma’s profitability.
Innate Pharma stock is trading at a EV to sales ratio of 2.0258 and a EV to EBITDA ratio of -5.4266. Its price to sales ratio in the trailing 12-months stood at 3.0969.
Innate Pharma stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $207.86 million
- Total Liabilities
- $41.34 million
- Operating Cash Flow
- $-197500.00
- Capital Expenditure
- $210000
- Dividend Payout Ratio
- 0%
Innate Pharma ended 2024 with $207.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $207.86 million while shareholder equity stood at $54.15 million.
Innate Pharma ended 2024 with $0 in deferred long-term liabilities, $41.34 million in other current liabilities, 4011000.00 in common stock, $-330316000.00 in retained earnings and $-40997000.00 in goodwill. Its cash balance stood at $84.23 million and cash and short-term investments were $101.49 million. The company’s total short-term debt was $2,102,000 while long-term debt stood at $0.
Innate Pharma’s total current assets stands at $139.83 million while long-term investments were $0 and short-term investments were $17.26 million. Its net receivables were $38.35 million compared to accounts payable of $20.91 million and inventory worth $-2000.00.
In 2024, Innate Pharma's operating cash flow was $-197500.00 while its capital expenditure stood at $210000.
Comparatively, Innate Pharma paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.97
- 52-Week High
- $3.97
- 52-Week Low
- $1.9
- Analyst Target Price
- $8.2
Innate Pharma stock is currently trading at $2.97 per share. It touched a 52-week high of $3.97 and a 52-week low of $3.97. Analysts tracking the stock have a 12-month average target price of $8.2.
Its 50-day moving average was $2.99 and 200-day moving average was $3.02 The short ratio stood at 13.82 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 61.5% are held by institutions.
Frequently Asked Questions About Innate Pharma
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.